First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Inclusion criteria

• ✓. 4 cycles of hypomethylating agents (HMA) or
• ✓. 2 cycles HMA + venetoclax b) Early relapse (ER) AML, defined as AML in relapse with CR, CRh or CRi duration less than 6 months on prior induction treatment c) Leukemia in first or higher relapse d) For participants aged 1 (for France: 2 years) to less than 18 years old, primary induction failure is defined as disease refractory after two cycles of induction therapy.
• ✓. intermediate or high-risk category as per a Revised International Prognostic Scoring System (IPSS-R) AND
• ✓. confirmed CD123 + expression status determined by local institutional standards AND
• ✓. limited to those with no available (or are ineligible) therapy with known clinical benefit.